US 5,972,704 AGranted

HIV nef targeted ribozymes

AssigneeRibozyme Pharmaceuticals, Inc.

InventorsKenneth G. Draper, Bharat Chowrira, James McSwiggen, Dan T. Stinchcomb, James D. Thompson

Life of this patent

Estimating the term…

Abstract

An enzymatic nucleic acid molecule which cleaves an immunodeficiency virus RNA in a gene required for viral replication, e.g., the nef or tat gene regions.

Claims22

Dependent claims

An enzymatic nucleic acid molecule which specifically cleaves RNA encoded by the nef gene of human immunodeficiency virus.

Dependencies are inferred from the claim text.

Facts

Application: 08/910,408Filed 13 Aug 1997 · continuation
Priority: 14 May 1992
Granted: 26 Oct 1999
Term ends: Not estimatedThe source records don’t support an estimate.

Classification23 codes

C12N 15/1132
Against viruses: against retroviridae, e.g. HIV
C07K 14/005
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: from viruses
C12N 15/85
Vectors or expression systems specially adapted for eukaryotic hosts: for animal cells
C12N 15/86
For animal cells: viral vectors

Family

Serial882,886Parent of this continuation-in-part · filed 14 May 1992
Serial103,423Parent of this continuation-in-part · filed 6 Aug 1993
Serial271,880Parent of this continuation · filed 7 Jul 1994
US 5,693,535 AParent of this continuation
US 5,972,704 AThis patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results